The EBN visited Rome in November as a speaker at 'BioEconomy Rome 2012', delivering a message on factors hindering the translation of science.
18.10.2012 – The EBN delivered the SME stream as part of BioPartnering Future Europe in Brussels and completed its work for the last FP7 health deadlines, building and supporting 5 consortia into topics including anti-infectives and cancer immunology, with European and US partners working together.
28.09.2012 – The EBN chaired a workshop on skills development for the biotech industry in Finland, and assisted three SME-driven consortia for the FP7 health deadline around the topic of anti-infectives.
25.07.2012 – The EBN supported the submission of a pan-European proposal for the Innovative medicines Initiative, bringing together 15 organisations from industry and academia around anti-infective research.
28.06.2012 – The EBN held a call for industry-experienced evaluators in FP7 and attracted over 40 applicants for new technologies calls in the health programme for the autumn 2012. BIO2102 in Boston, also took place and the EBN extended its partner-building activities with the NIH for joint EU-US projects.
22.05.2012 – May saw EBN-supported proposals for the Innovative Medicines Initiative (IMI) submitted. Two proposals, with strong SME participation, were submitted with a total value of €100 million, with the mission to revolutionize lead discovery and development in novel medicines.
27.04.2012 – April saw a busy month with the support of SME-driven consortia for the current Innovative Medicines Initiative call. SMEs plus academic partners met at the Network Headquarters to design and develop proposals for submission to the May deadline.
30.03.2012 – US partnerships was the theme for March, with our workshop 'Doing business in the US' on March 29th and the Network's conference 'Building Transatlantic Partnerships' on March 30th. The 'Partnerships' meeting at the Swiss Mission in central Brussels focussed on funding from the EC, NIH, US Department of Defense and Bill and Melinda Gates Foundation as a tool to build partnerships. The Network also launched an initiative to build FP7 applications with NIH researchers, which will run through the summer.
17.02.2012 – Dr. Claire Skentelbery, Secretary General of the European Biotechnology Network chaired the '5th Berlin conference on IP in Life Sciences'. The meeting focussed on antibodies and the challenges that they face in complex IP management. Some 100 experts focused on this issue in the impressive rooms of the Swiss Embassy near the Federal Chancellery. A short video about the conference is online at: www.youtube.com/watch
25.01.2012 – The EBN has launched an ERASMUS project with the University of Pecs, Sanofi-Aventis and Finish SME Personmed with the mission to help universities to evolve teaching to produce industry-relevant biotechnology graduates. The Network will bring together an industry panel to provide input to recommendations.
Membership - Join the Network!
Basic Membership for natural persons is free, while Advanced Membership for professionals including premium services costs only €100 p.a.
Click here to apply for network membership!
European Biotechnology Network AISBL
Rue de la Science 14b
1040 Brussels, Belgium
Tel: +32 2 588 70 71